SEARCH:   Advanced

Blood, 1 March 2008, Vol. 111, No. 5, pp. 2521-2526. Prepublished online as a Blood First Edition Paper on September 27, 2007; DOI 10.1182/blood-2007-08-104984. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-08-104984v1 111/5/2521    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Brenner, H. Articles by Pulte, D. Search for Related Content PubMed PubMed Citation Articles by Brenner, H. Articles by Pulte, D. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Recent major improvement in long-term survival of younger patients with multiple myeloma Hermann Brenner1, Adam Gondos1, and Dianne Pulte1,2 1 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany; and 2 Weill Cornell Medical Center, New York, NY In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5- and 10-year relative survival of patients with MM in the United States from 1990-1992 to 2002-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Techniques of period analysis were used to show most recent developments. Overall, 5-year relative survival increased from 28.8% to 34.7% (P < .001), and 10-year relative survival increased from 11.1% to 17.4% (P < .001) between 1990-1992 and 2002-2004. Much stronger increases were seen in the age group younger than 50 years, leading to 5- and 10-year relative survival of 56.7% and 41.3% in 2002-2004, and in the age group 50 to 59 years, leading to 5- and 10-year relative survival of 48.2% and 28.6% in 200-2004. By contrast, only moderate improvement was seen in the age group 60 to 69 years, and essentially no improvement was achieved among older patients. Our period analysis discloses a major increase in long-term survival of younger patients with MM in recent years, which most likely reflects the effect of recent advances in therapy and their dissemination in clinical practice. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The road to cure in multiple myeloma Irene M. Ghobrial and Kenneth C. Anderson Blood 2008 111: 2503. [Full Text] [PDF] This article has been cited by other articles: H. Ludwig, B. G. M. Durie, V. Bolejack, I. Turesson, R. A. Kyle, J. Blade, R. Fonseca, M. Dimopoulos, K. Shimizu, J. San Miguel, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group Blood, April 15, 2008; 111(8): 4039 - 4047. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020